Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Aging is the primary risk factor for CVD, in large part due to adverse modifications to the arteries. These modifications include vascular endothelial dysfunction and arterial stiffness. Vascular endothelial dysfunction is an initiating step in atherosclerosis, and is primarily caused by reduced nitric oxide (NO) bioavailability secondary to excessive superoxide-driven oxidative stress and inflammation. Endothelial dysfunction leads to arterial stiffness and the development of hypertension (HTN) which further increases CVD. Greater than 2/3 of the US population has elevated blood pressure or stage 1-HTN. As such, interventions that improve vascular endothelial dysfunction by increasing NO bioavailability and mitigating excessive oxidative stress and inflammation are needed. Blueberries are rich in bioactive compounds including flavonoids, phenolic acids, and pterostilbene. These compounds and their metabolites have been shown to attenuate oxidative stress and inflammation. The primary goal of this study is to assess the efficacy of blueberries to improve reduce blood pressure and improve vascular endothelial dysfunction and arterial stiffness in middle-aged/older men with elevated blood pressure or stage 1-HTN.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
58
22 g/day wild blueberry powder
22 g/day placebo powder
Food and Nutrition Clinical Research Laboratory
Fort Collins, Colorado, United States
Reactive hyperemia index
Endothelial function assessed as reactive hyperemia index using peripheral arterial tonometry (EndoPat)
Time frame: Baseline to 12 Weeks
Augmentation index
Arterial stiffness assessed as augmentation index using an automated blood pressure monitor (SphygmoCor)
Time frame: Baseline to 12 Weeks
Pulse wave velocity
Arterial stiffness assessed as carotid-femoral pulse wave velocity using an automated blood pressure monitor (SphygmoCor)
Time frame: Baseline to 12 Weeks
Endothelial cell protein expression
Protein expression will be assessed as an exploratory analysis for markers of nitric oxide bioavailability, inflammation, and/or oxidative stress will be measured by quantitative immunofluorescence in biopsied venous endothelial cells
Time frame: Baseline to 12 Weeks
Hemoglobin A1c
Blood hemoglobin A1C will be measured
Time frame: Baseline to 12 Weeks
Lipid profile
Blood lipid profiles will be measured
Time frame: Baseline to 12 Weeks
Nitric oxide metabolites
Blood nitrate/nitrite will be measured
Time frame: Baseline to 12 Weeks
ICAM-1
Blood ICAM-1 will be measured
Time frame: Baseline to 12 Weeks
VCAM-1
Blood VCAM-1 will be measured
Time frame: Baseline to 12 Weeks
Blood pressure
Brachial and Aortic blood pressure (systolic blood pressure, diastolic blood pressure, pulse pressure, aortic pressure) assessed using an automated blood pressure monitor (SphygmoCor)
Time frame: Baseline to 12 Weeks
Gut microbiota
Determine the effects on stool sample microbial populations
Time frame: Baseline to 12 Weeks
Plasma blueberry polyphenol metabolites
Targeted analysis of plasma metabolites by GC-MS and LC-MS
Time frame: Baseline to 12 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.